Published in Antimicrob Agents Chemother on June 11, 2012
Metronidazole for Pulmonary Tuberculosis (South Korea) | NCT00425113
Linezolid to Treat Extensively-Drug Resistant Tuberculosis | NCT00727844
Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat Med (2013) 1.91
Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother (2013) 1.47
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol (2014) 1.46
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev (2015) 1.45
The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med (2015) 1.40
Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect Immun (2013) 1.16
Early Changes by (18)Fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun (2014) 1.08
Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery. Proc Natl Acad Sci U S A (2015) 1.04
Host-directed therapeutics for tuberculosis: can we harness the host? Microbiol Mol Biol Rev (2013) 0.97
Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice. Antimicrob Agents Chemother (2014) 0.96
Modeling tuberculosis in nonhuman primates. Cold Spring Harb Perspect Med (2014) 0.95
Inflammatory signaling in human tuberculosis granulomas is spatially organized. Nat Med (2016) 0.92
Within patient microevolution of Mycobacterium tuberculosis correlates with heterogeneous responses to treatment. Sci Rep (2015) 0.91
Lipidomic analysis links mycobactin synthase K to iron uptake and virulence in M. tuberculosis. PLoS Pathog (2015) 0.88
18-Fluorodeoxyglucose positron emission tomography for tuberculosis diagnosis and management: a case series. BMC Pulm Med (2013) 0.86
A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets. Antimicrob Agents Chemother (2015) 0.85
Exploitation of Mycobacterium tuberculosis reporter strains to probe the impact of vaccination at sites of infection. PLoS Pathog (2014) 0.85
Immunometabolism within the tuberculosis granuloma: amino acids, hypoxia, and cellular respiration. Semin Immunopathol (2015) 0.84
Nuclear imaging: a powerful novel approach for tuberculosis. Nucl Med Biol (2014) 0.84
The Warburg effect in mycobacterial granulomas is dependent on the recruitment and activation of macrophages by interferon-γ. Immunology (2015) 0.84
Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9. Dis Model Mech (2016) 0.81
Mycobacterium-Infected Dendritic Cells Disseminate Granulomatous Inflammation. Sci Rep (2015) 0.78
Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med (2016) 0.77
Asymptomatic primary tuberculous pleurisy with intense 18-fluorodeoxyglucose uptake mimicking malignant mesothelioma. BMC Infect Dis (2013) 0.77
Clinical and radiographic differentiation of lung nodules caused by mycobacteria and lung cancer: a case-control study. BMC Infect Dis (2015) 0.75
Perspectives for Developing New Tuberculosis Vaccines Derived from the Pathogenesis of Tuberculosis: I. Basic Principles, II. Preclinical Testing, and III. Clinical Testing. Vaccines (Basel) (2013) 0.75
FDG Uptake in Lymphoid Tissue serves as a Predictor of Disease Outcome in the Nonhuman Primate Model of Monkeypox Infection. J Virol (2017) 0.75
Application of a whole blood mycobacterial growth inhibition assay to study immunity against Mycobacterium tuberculosis in a high tuberculosis burden population. PLoS One (2017) 0.75
Positron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α4β1-Expressing Immune Cells. J Immunol (2017) 0.75
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med (2009) 12.92
OsiriX: an open-source software for navigating in multidimensional DICOM images. J Digit Imaging (2004) 11.92
An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature (2010) 10.37
Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun (2008) 4.93
Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun (2003) 4.16
The action of antituberculosis drugs in short-course chemotherapy. Tubercle (1985) 3.69
A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med (2004) 3.24
Pulmonary tuberculosis: up-to-date imaging and management. AJR Am J Roentgenol (2008) 3.12
Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest (2009) 2.78
Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology (2000) 2.55
Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother (2009) 2.18
Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors. J Nucl Med (2008) 2.15
Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res (2000) 2.13
Pulmonary tuberculosis: CT findings--early active disease and sequential change with antituberculous therapy. Radiology (1993) 2.06
Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis (2010) 2.00
On the response of genetically resistant and susceptible rabbits to the quantitative inhalation of human type tubercle bacilli and the nature of resistance to tuberculosis. J Exp Med (1952) 1.99
Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet (1980) 1.97
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother (2008) 1.95
Radiological manifestations of pulmonary tuberculosis. Eur J Radiol (2004) 1.89
Evaluation of adapted whole-blood interferon-gamma release assays for the diagnosis of pleural tuberculosis. Respiration (2008) 1.71
Cavitary tuberculosis produced in rabbits by aerosolized virulent tubercle bacilli. Infect Immun (1996) 1.68
Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis (Edinb) (2008) 1.67
Different strains of Mycobacterium tuberculosis cause various spectrums of disease in the rabbit model of tuberculosis. Infect Immun (2003) 1.63
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother (2011) 1.50
The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb) (2007) 1.49
Virulence of Mycobacterium tuberculosis CDC1551 and H37Rv in rabbits evaluated by Lurie's pulmonary tubercle count method. Infect Immun (1999) 1.46
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother (2004) 1.44
Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis (2010) 1.41
Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proc Natl Acad Sci U S A (1999) 1.38
A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis (1998) 1.37
Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrob Agents Chemother (2010) 1.37
Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. Chest (2003) 1.32
Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. Int J Tuberc Lung Dis (2010) 1.21
Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis. Infect Immun (2004) 1.18
Assessment of lung inflammation with 18F-FDG PET during acute lung injury. AJR Am J Roentgenol (2010) 1.17
Biomarkers for tuberculosis disease status and diagnosis. Curr Opin Pulm Med (2009) 1.09
Pulmonary bovine-type tuberculosis in rabbits: bacillary virulence, inhaled dose effects, tuberculin sensitivity, and Mycobacterium vaccae immunotherapy. Clin Diagn Lab Immunol (1998) 1.07
CCL2 responses to Mycobacterium tuberculosis are associated with disease severity in tuberculosis. PLoS One (2009) 1.07
Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med (2008) 1.05
Autoradiographic quantification of 18F-FDG uptake in experimental soft-tissue abscesses in rats. Radiology (2002) 1.00
Double-phase 18F-FDG PET-CT for determination of pulmonary tuberculoma activity. Eur J Nucl Med Mol Imaging (2007) 0.99
Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography. Nucl Med Commun (2008) 0.95
Liquefaction and cavity formation in pulmonary TB: a simple method in rabbit skin to test inhibitors. Tuberculosis (Edinb) (2009) 0.94
The value of end-of-treatment chest radiograph in predicting pulmonary tuberculosis relapse. Int J Tuberc Lung Dis (2008) 0.93
Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis. Antimicrob Agents Chemother (2002) 0.91
Inflammation imaging. Proc Am Thorac Soc (2005) 0.88
Immunoprofile studies in patients with pulmonary tuberculosis. II. Correlation of levels of different classes of immunoglobulins and specific antibodies with the extent of tuberculosis. Scand J Respir Dis (1979) 0.87
Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol. Pharmacol Res (2003) 0.85
Comparative bioequivalence study of rifampicin and isoniazid combinations in healthy volunteers. Int J Tuberc Lung Dis (1999) 0.84
The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET. Ann Nucl Med (2008) 0.84
Evaluation of pulsed high intensity focused ultrasound exposures on metastasis in a murine model. Clin Exp Metastasis (2009) 0.82
A review of murine models of latent tuberculosis infection. Scand J Infect Dis (2011) 0.81
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet (2012) 6.78
A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature (2004) 6.29
Spiroindolones, a potent compound class for the treatment of malaria. Science (2010) 5.94
Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med (2012) 5.87
Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell (2005) 5.75
Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun (2008) 4.93
The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem (2004) 4.75
PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science (2008) 4.74
Ambient air pollution exaggerates adipose inflammation and insulin resistance in a mouse model of diet-induced obesity. Circulation (2009) 4.71
Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest (2008) 4.41
Tuberculosis - metabolism and respiration in the absence of growth. Nat Rev Microbiol (2005) 4.38
Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science (2011) 4.13
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2005) 3.97
Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science (2009) 3.73
Age and the epidemiology and pathogenesis of tuberculosis. Lancet (2010) 3.37
DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell (2003) 3.36
Tuberculosis: what we don't know can, and does, hurt us. Science (2010) 3.29
Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01
Understanding latent tuberculosis: a moving target. J Immunol (2010) 2.95
Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun (2005) 2.89
Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest (2009) 2.78
Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem (2003) 2.63
Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun (2006) 2.63
The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci U S A (2003) 2.60
Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis (2012) 2.53
Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J Infect Dis (2005) 2.50
A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun (2010) 2.49
Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis. Infect Immun (2004) 2.47
The W-Beijing lineage of Mycobacterium tuberculosis overproduces triglycerides and has the DosR dormancy regulon constitutively upregulated. J Bacteriol (2007) 2.42
SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 2.41
Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther (2006) 2.41
Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis. J Med Chem (2006) 2.37
Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biol Psychiatry (2002) 2.26
An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A (2009) 2.20
Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One (2010) 2.14
Proteasomal protein degradation in Mycobacteria is dependent upon a prokaryotic ubiquitin-like protein. J Biol Chem (2008) 2.12
Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry (2006) 2.09
Species-specific calls evoke asymmetric activity in the monkey's temporal poles. Nature (2004) 2.04
HIV-1/mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis? Infect Immun (2011) 2.03
The role of MmpL8 in sulfatide biogenesis and virulence of Mycobacterium tuberculosis. J Biol Chem (2004) 1.99
Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing. Cell (2013) 1.96
Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology (2009) 1.95
Prospects for new antitubercular drugs. Curr Opin Microbiol (2004) 1.94
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med (2013) 1.93
Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry (2004) 1.92
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement (2013) 1.87
Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. J Bacteriol (2002) 1.86
Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J Med Chem (2010) 1.84
Targeted drug delivery by thermally responsive polymers. Adv Drug Deliv Rev (2002) 1.80
Design of thermally responsive, recombinant polypeptide carriers for targeted drug delivery. Adv Drug Deliv Rev (2002) 1.71
Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis (2008) 1.67
High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal Chem (2011) 1.64
Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. J Immunol (2013) 1.62
Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis. J Biol Chem (2003) 1.62
Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol (2009) 1.62
Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem (2008) 1.62
P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. J Nucl Med (2010) 1.62
Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci (2004) 1.61
A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem Biol (2012) 1.59
Single-stranded DNA-binding proteins regulate the abundance of LIM domain and LIM domain-binding proteins. Genes Dev (2007) 1.57
A comparative lipidomics platform for chemotaxonomic analysis of Mycobacterium tuberculosis. Chem Biol (2011) 1.56
The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol (2009) 1.53
P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. J Nucl Med (2008) 1.53
Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. J Bacteriol (2002) 1.52
The 5-HT1A receptor and 5-HT transporter in temporal lobe epilepsy. Neurology (2013) 1.51
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother (2011) 1.50
Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit Vx2 tumor model. J Control Release (2011) 1.49
Genetic diversity of Mycobacterium tuberculosis isolates from a tertiary care tuberculosis hospital in South Korea. J Clin Microbiol (2009) 1.49
Contribution of CD8+ T cells to control of Mycobacterium tuberculosis infection. J Immunol (2006) 1.49
Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis (2007) 1.49
IQGAP1 regulates cell motility by linking growth factor signaling to actin assembly. J Cell Sci (2007) 1.49
Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. J Control Release (2006) 1.48
Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci U S A (2012) 1.48
IFN-γ from CD4 T cells is essential for host survival and enhances CD8 T cell function during Mycobacterium tuberculosis infection. J Immunol (2012) 1.47
Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) (2012) 1.47
Use of low tidal volume in septic shock may decrease severity of subsequent acute lung injury. Shock (2004) 1.46
Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. PLoS Pathog (2011) 1.45
The hippocampus plays a selective role in the retrieval of detailed contextual memories. Curr Biol (2010) 1.45
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev (2015) 1.45
Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science (2012) 1.44
Increased myocardial perfusion and sympathoadrenal activation during mild core hypothermia in awake humans. Clin Sci (Lond) (2003) 1.44
Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis. J Clin Microbiol (2009) 1.43
Top down characterization of secreted proteins from Mycobacterium tuberculosis by electron capture dissociation mass spectrometry. J Am Soc Mass Spectrom (2003) 1.41
Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain. J Med Chem (2006) 1.41
Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure-activity relationships of the nucleobase domain of 5'-O-[N-(salicyl)sulfamoyl]adenosine. J Med Chem (2008) 1.40
5'-O-[(N-acyl)sulfamoyl]adenosines as antitubercular agents that inhibit MbtA: an adenylation enzyme required for siderophore biosynthesis of the mycobactins. J Med Chem (2007) 1.39
A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. Proc Natl Acad Sci U S A (2013) 1.39
Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res (2012) 1.38
In vivo phenotypic dominance in mouse mixed infections with Mycobacterium tuberculosis clinical isolates. J Infect Dis (2005) 1.36
Impact of diabetes and smoking on mortality in tuberculosis. PLoS One (2013) 1.36
Imidazolopiperazines: hit to lead optimization of new antimalarial agents. J Med Chem (2011) 1.36
Structural optimization of a "smart" doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors. J Control Release (2005) 1.35